Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

1a). There was no substantial inhibition of food intake (Fig. 1b), suggesting that the weight loss was mediated through increased energy expenditure.

Can-Fite BioPharma Ltd. (NYSE: CANF), shares barely budged Monday as the biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory ...

Java Burn is a specially formulated coffee booster for weight loss. With eight different ingredients designed to ignite the ...

The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Lizzo is feeling "Good as Hell" as she celebrates a major milestone in her weight loss journey. The "About Damn Time" singer, 36, shared Saturday on Instagram that she has "reached my weight ...

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

Ozempic and other semaglutide medications have skyrocketed in popularity as weight-loss aids, with prescriptions surging by ...

As Alzheimer’s disease is the most common form of dementia — affecting an estimated 6.7 million Americans — it’s not surprising that people who experience memory loss may suspect AD.